This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Science 37 Holdings Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Science 37 Holdings kazanç ve gelirinin sırasıyla yıllık 66.7% ve 17.5% oranında artması tahmin edilirken, EPS'nin yıllık 67.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

66.7%

Kazanç büyüme oranı

67.90%

EPS büyüme oranı

Life Sciences kazanç büyümesi	17.6%
Gelir büyüme oranı	17.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	30 Jan 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Dec 18

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

With a price-to-sales (or "P/S") ratio of 0.5x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) may be sending very bullish...

Analiz Makalesi • Apr 17

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

You may think that with a price-to-sales (or "P/S") ratio of 0.6x Science 37 Holdings, Inc. ( NASDAQ:SNCE ) is...

Seeking Alpha • Aug 18

Science 37, Syapse team for faster patient enrollment in cancer trials

Science 37 (NASDAQ:SNCE) Syapse said they are collaborating to deploy proprietary real-world data intelligence and analytics to help identify suitable patients for oncology clinical trials, thus helping speed up the enrollment process. "By partnering with Syapse, we will have the ability to tap into advanced data-intelligence capabilities to make effective trial identification and recruitment a reality for patients and sponsors," said Science 37 Chief Medical Officer Jonathan Cotliar.

Seeking Alpha • Aug 11

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 press release (NASDAQ:SNCE): Q2 GAAP EPS of -$0.05 beats by $0.19. Revenue of $19.3M (+53.8% Y/Y) misses by $0.2M. Net bookings were $25.4M for the quarter ended June 30, 2022, compared to $44.1M for the same period in 2021. Adjusted EBITDA was -$16.5M for the quarter ended June 30, 2022, compared to -$5.4M in the same period in 2021. Science 37 is providing revenue guidance of $76 million to $86 million vs. consensus of $92.24M and adjusted EBITDA guidance of $(65) million to $(69) million for the fiscal year ending December 31, 2022.

Analiz Makalesi • May 13

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a sad week for Science 37 Holdings, Inc. ( NASDAQ:SNCE ), who've watched their investment drop 20% to US$3.03...

Analiz Makalesi • Apr 11

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Seeking Alpha • Jan 02

Science 37: Pioneering Decentralized Clinical Trials

Science 37 pioneered the concept of decentralized clinical trials. The Covid-19 pandemic drove more demand for DCTs. The Company is a leader in its niche DCT market worth over $60 billion.

Analiz Makalesi • Nov 04

We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:SNCE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	95	3	-18	30	3
12/31/2025	75	-25	-28	3	3
12/31/2024	63	-38	-44	-9	4
12/31/2023	58	-73	-81	-46	4
9/30/2023	60	-125	-74	-48	N/A
6/30/2023	62	-134	-84	-58	N/A
3/31/2023	66	-121	-98	-67	N/A
12/31/2022	70	-51	-107	-75	N/A
9/30/2022	75	-50	-115	-82	N/A
6/30/2022	73	-41	-108	-78	N/A
3/31/2022	66	-43	-83	-57	N/A
12/31/2021	60	-94	-57	-36	N/A
9/30/2021	50	-42	-37	-23	N/A
6/30/2021	43	-35	-33	-23	N/A
3/31/2021	33	-33	-33	-26	N/A
12/31/2020	24	-32	-32	-25	N/A
12/31/2019	14	-18	-20	-16	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SNCE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: SNCE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: SNCE önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: SNCE şirketinin gelirinin (yıllık 17.5% ) US pazarından (yıllık 11.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SNCE şirketinin gelirinin (yıllık 17.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SNCE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/03/11 11:43
Gün Sonu Hisse Fiyatı	2024/03/11 00:00
Kazançlar	2023/09/30
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Science 37 Holdings, Inc. 6 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Eric Coldwell	Baird
Matthew Hewitt	Craig-Hallum Capital Group LLC
Frank Takkinen	Lake Street Capital Markets, LLC

This company has been acquired

Science 37 Holdings Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 51% to US$13.83

Forecast to breakeven in 2026

Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

Price target decreased by 20% to US$1.50

Consensus estimates of losses per share improve by 11%

Price target decreased by 9.4% to US$1.81

Recent updates

Science 37 Holdings, Inc. Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Holdings, Inc. Metasite Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Holdings, Inc. Delivers 22x Faster Enrollment Than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Holdings Files Form 15

Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index

eMed, LLC completed the acquisition of Science 37 Holdings, Inc. (NasdaqCM:SNCE).

eMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc. (NasdaqCM:SNCE) $37.8 million.

Price target decreased by 51% to US$13.83

New major risk - Share price stability

Forecast to breakeven in 2026

Science 37 Holdings Regains Compliance with Minimum Closing Bid Price Requirement for Continued Listing on NASDAQ Capital Market

Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks

Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

Price target decreased by 20% to US$1.50

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Science 37 Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CEO & Director exercised options and sold US$64k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Science 37 Holdings Announces Nasdaq Approves an Additional 180 Calendar Day Compliance Period to Regain Compliance with the Minimum Bid Requirement

Consensus estimates of losses per share improve by 11%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)

Price target decreased by 9.4% to US$1.81

High number of new and inexperienced directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Science 37 Holdings, Inc. (NasdaqGM:SNCE) acquired Life Sciences Platform of Vault Health.

Science 37 Holdings Receives A Deficiency Notification Letter from Nasdaq Regarding Minimum Bid Price

Consensus revenue estimates fall by 15%

Price target decreased to US$3.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Science 37 Holdings, Inc. Revises Earnings Guidance for the Full Year 2022

Science 37 Holdings, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Science 37 Holdings, Inc. Announces Board Changes

Science 37 Holdings, Inc. Appoints Michael Shipton as Chief Commercial Officer

Science 37 Holdings, Inc. and Syapse Partner to Enable Faster Patient Enrollment in Oncology Clinical Trials

Consensus forecasts updated

Science 37, Syapse team for faster patient enrollment in cancer trials

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Science 37 Holdings, Inc. Provides Revenue Guidance for Year Ending December 31, 2022

Science 37 reports Q2 mixed earnings; narrows FY22 guidance

Science 37 Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Oncology Clinical Trial Execs to Increase Decentralization, Science 37 Survey Indicates

Consensus estimates of losses per share improve by 72%

Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Science 37 Introduces Virtual Site Model to Rescue Slow Enrolling Clinical Trials

Science 37® Announces NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct

First quarter 2022 earnings: Revenues exceed analyst expectations

Science 37 Holdings, Inc. Provides Revenue Guidance for the Fiscal Year Ending December 31, 2022

Price target decreased to US$11.33

Science 37 Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans

Science 37 Holdings, Inc. Adds Shaalan Beg to Its Global Management Team

Consensus revenue estimates fall by 12%